1) RECIPIENT shall be a non-profit research organization, or a university or other institution of higher education, or a government agency conducting research. 2) In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Microbiol Immunol. 2003 47(8):613-617) designated by the DEPOSITOR is required. 3) RECIPIENT shall use the BI0LOGICAL RESOURCE solely for internal research which means cultivation, storage and accessibility test. 4) RECIPIENT shall not undertake the Research jointly with any third parties or entrust the Research to any third parties without the prior written consent of DEPOSITOR. 5) RECIPIENT shall neither use the BIOLOGICAL RESOURCE for any purpose other than the Research nor provide the Material to any third parties without the prior written consent of DEPOSITOR. 6) The RECIPIENT shall contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 7) When publishing the Research and the Research Results, RECIPIENT shall notify DEPOSITOR in writing in advance of such publication. the timing, and method, etc., and shall consult with DEPOSITOR. 8) When Publishing as provided for in the preceding paragraph, RECIPIENT shall， in accordance with a request from DEPOSITOR/DEVELOPER, acknowledge that DEVELOPER ( Dr. Naoto Ito and Dr. Makoto Sugiyama) is the source of the BIOLOGICAL RESOURCE.
Remarks
approver's address
×
English
Address
Gifu University, 1-1 Yanagido, Gifu City 501-1193, JAPAN
Dr.Ito Naoto
Fax. +81-58-293-2949
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
4556
Ito N, Takayama-Ito M, Yamada K, Hosokawa J, Sugiyama M, Minamoto N.
Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system.Microbiol Immunol.
2003
47(8):613-617
PubMed ID: 14524622
DOI: 10.1111/j.1348-0421.2003.tb03424.x
22117
Takahashi T, Amarbayasgalan S, Ueno S, Sugiura Y, Dorjsuren E, Shimizu K, Kamitani W.
Lethal model for respiratory syncytial virus infection using C57BL/6 miceJ Virol
2024
e0177224
PubMed ID: 39498987
DOI: 10.1128/jvi.01772-24
19694
Takahashi T, Ueno S, Sugiura Y, Shimizu K, Kamitani W.
Establishment of a new reverse genetics system for respiratory syncytial virus under the control of RNA polymerase IIMicrobiol Immunol
2023
67(9):413-421
PubMed ID: 37424190
DOI: 10.1111/1348-0421.13088
19812
Watanabe Y, Sakuma C, Yaginuma H.
Tangentially migrating cells differentiate into stratum griseum central neurons to form tectofugal visual pathway in the developing chick optic tectumDev Dyn
2023
252(8):1096-1112
PubMed ID: 36734001
DOI: 10.1002/dvdy.572
21144
Itakura Y, Tabata K, Morimoto K, Ito N, Chambaro HM, Eguchi R, Otsuguro KI, Hall WW, Orba Y, Sawa H, Sasaki M.
Glu333 in rabies virus glycoprotein is involved in virus attenuation through astrocyte infection and interferon responses.iScience
2022
25(4):104122
PubMed ID: 35402872
DOI: 10.1016/j.isci.2022.104122
16286
Yun SM, Lee TY, Lim HY, Ryou J, Lee JY, Kim YE.
Development and Characterization of a Reverse Genetics System for a Human-Derived Severe Fever With Thrombocytopenia Syndrome Virus Isolate From South KoreaFront Microbiol
2021
12:772802
PubMed ID: 34867909
DOI: 10.3389/fmicb.2021.772802
Back
Top
CELL BANK Website
